CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD⁺-Lowering Agents

• Main Authors: Pamela Becherini (Author), Debora Soncini (Author), Silvia Ravera (Author), Elisa Gelli (Author), Claudia Martinuzzi (Author), Giulia Giorgetti (Author), Antonia Cagnetta (Author), Fabio Guolo (Author), Federico Ivaldi (Author), Maurizio Miglino (Author), Sara Aquino (Author), Katia Todoerti (Author), Antonino Neri (Author), Andrea Benzi (Author), Mario Passalacqua (Author), Alessio Nencioni (Author), Ida Perrotta (Author), Maria Eugenia Gallo Cantafio (Author), Nicola Amodio (Author), Antonio De Flora (Author), Santina Bruzzone (Author), Roberto M. Lemoli (Author), Michele Cea (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cancer cells fuel growth and energy demands by increasing their NAD⁺ biosynthesis dependency, which therefore represents an exploitable vulnerability for anti-cancer strategies. CD38 is a NAD⁺-degrading enzyme that has become crucial for anti-MM therapie...